Clinical Trial Detail

NCT ID NCT04092179
Title Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers
Recruitment Not yet recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors University Health Network, Toronto
Indications

myelodysplastic syndrome

acute myeloid leukemia

myeloproliferative neoplasm

Therapies

Enasidenib + Venetoclax

Age Groups: adult senior

Additional content available in CKB BOOST